About the Study

Acute Myeloid Leukemia (AML): A clinical study of enasidenib to treat relapsed/refractory AML with IDH-2 mutations

This study is for: • Patients who are between the age of 2 and 18 years old • Have been diagnosed with Acute Myeloid Leukemia (AML) that has relapsed (has come back) or is refractory (has not responded to earlier treatment) • The AML also must have a specific genetic change, also called a mutation, in a protein called IDH2 The overall goal of this study is to find out what effects, good and/or bad, the drug enasidenib has on children and adolescents with AML with IDH2 mutations.

Interested in learning more?

Full Study Name: ADVL18P1 -An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation